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Cellular protein homeostasis is tightly regulated by ubiquitination. Responsible for target 
protein ubiquitination is a class of enzymes, the so-called ubiquitin E3 ligases. They 
are opposed to a second class of enzymes, called deubiquitinating enzymes (DUBs), 
which can remove polyubiquitin chains from their specific target proteins. The coaction 
of the two sets of enzymes allows the cell to adapt its overall protein content and the 
abundance of particular proteins to a variety of cellular and environmental stresses, 
including hypoxia. In recent years, DUBs have been highlighted to play major roles in 
many diseases, including cancer, both as tumor suppressors and oncogenes. Therefore, 
DUBs are emerging as promising targets for cancer-cell specific treatment. Here, we will 
review the current understanding of DUBs implicated in the control of hypoxia-inducible 
factor, the regulation of DUBs by hypoxia, and the use of DUB-specific drugs to target 
tumor hypoxia-signaling.
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inTRODUCTiOn
Like most other posttranslational modifications (PTMs), ubiquitin (Ub) conjugation is a reversible 
modification (1). Ub E3 ligases covalently attach monomers of Ub to lysine (and also cysteine) 
residues of their target proteins. Furthermore, ligases also convert monoubiquitination into poly-
ubiquitin chains by attaching one by one further Ub monomers to one of the seven internal lysine 
residues (K6/K11/K27/K29/K33/K48/K63) of the preceding Ub molecule. In contrast, the family of 
DeUBiquitinating enzymes (DUBs) breaks down those mono- and polyubiquitin chains from the 
target protein. Besides counteracting the action of the Ub E3 ligases, DUBs are proteases that process 
Ub precursors.
Of the nearly 100 DUBs encoded by the human genome, 79 are predicted to be active and mostly 
cleave particular types of Ub chain linkages from their respective target proteins. DUBs can be 
grouped into six families based on sequence and structure similarity: ubiquitin-specific proteases 
(USPs) that comprise the largest and most diverse subfamily, ubiquitin carboxyl-terminal hydrolases 
(UCHs), ovarian tumor proteases (OTUs), Josephins, JAB1/MPN/MOV34 (JAMMs), and the more 
recently discovered monocyte chemotactic protein-induced proteins (MCPIP). With the exception 
of JAMMs, which belong to the Zn2+-dependent metalloproteases, all the rest use the classical 
cysteine protease triad in the catalytical side (2).
Classically, the reversal of the polyubiquitination protects the target protein from being degraded 
by the proteasome, but ubiquitination has also been shown to have a broad range of non-catabolic 
functions (3). Thus, it is not surprising that DUB activity or inappropriate expression impacts on the 
regulation of multiple biological processes and several signaling pathways that are frequently altered 
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in many disorders from cancer over neurodegenerative patholo-
gies to inflammatory diseases [for more details, please refer to 
Ref. (4)]. Because of their direct or indirect implications in those 
diseases and because of their potential druggability, DUBs have 
become of increasing interest in recent years.
Hypoxia is a feature of most human cancers (5). The cancer 
cells and their environment adapt to and survive under low 
oxygen availability. The activation of the hypoxia-inducible 
factor (HIF) that orchestrates the hypoxia-signaling pathway is 
instrumental to this adaptation. HIF is a heterodimeric transcrip-
tion factor that consists of a constitutively expressed β-subunit 
(HIF-β) and HIF-α, whose expression is tightly regulated 
through the ubiquitin-proteasome system (UPS) (6–8). HIF trig-
gers the expression of hundreds of direct target genes, indirect 
transcription factors, and non-coding RNAs that enable cancer 
cell survival and tumor progression by promoting, among oth-
ers, angiogenesis, metabolic rewiring, genomic instability, drug 
resistance, and the self-renewal capacity of cancer stem cells. HIFs 
are also activated by genetic alterations in human cancers, such 
as the von Hippel–Lindau protein (pVHL) loss of function in 
clear-cell renal carcinoma (9). Accordingly, sustained expression 
of HIF-α in tumors has been associated with higher aggressive-
ness, migratory, and metastasis-initiating potential and therefore 
worse prognosis (10, 11).
In this review, we will summarize the current knowledge about 
the action of DUBs on HIF-α and the regulation of those enzymes 
by hypoxia. We will also discuss the potential of exploiting DUBs 
to target tumor hypoxia signaling.
THe CAnOniCAL HiF SiGnALinG 
PATHwAY
The adaptive cellular program in response to low oxygen avail-
ability is mainly triggered by two HIF-α subunits (HIF-1α and 
HIF-2α), which share several common targets but also exhibit 
non-redundant functions (12). Anyhow, the levels of both 
HIF-α subunits result from the dynamic interplay between their 
ubiquitination and deubiquitination. In well-oxygenated cells, 
HIF-α is very unstable, as it is degraded by the proteasome within 
approximately <5 min after translation, whereas HIF-α’s half-life 
is greatly increased in hypoxia (7, 8, 13). Proteasomal degrada-
tion is triggered by the continuous polyubiquitination of HIF-α 
by pVHL (9). pVHL is part of an E3 ligase complex and binds to 
HIF-α after the hydroxylation of two designated proline residues 
in HIF-α’s oxygen-dependent degradation domain (ODDD), the 
central regulatory domain that confers its oxygen sensibility (8). 
This binding can be stabilized by SSAT2, therefore enhancing HIF-
α ubiquitination (14). The family of prolyl hydroxylase domain-
containing proteins (PHDs), the oxygen sensors also referred to 
as EGLNs or HPHs, catalyze the hydroxylation of HIF-α (Pro402 
and Pro564, in the case of HIF-1α) (15–19). HIF-α also harbors an 
N-terminal basic helix-loop-helix (bHLH) domain that mediates 
HIF-binding to the target DNA after heterodimerization with 
HIF-β/ARNT via the adjacent PAS domain. Of the two transacti-
vation domains (TAD), the N-terminal TAD (N-TAD) lies within 
the ODDD, while the C-terminal TAD (C-TAD) is responsible 
for the recruitment of CBP/p300 needed to successfully induce 
the transcription of the HIF target genes that are characterized 
by having one or more HREs (hypoxia response elements) (20, 
21). This C-TAD contains an asparagine residue (Asn803, in the 
case of HIF-1α) that upon oxygen-dependent hydroxylation by 
FIH (factor inhibiting HIF) hinders the successful interaction of 
HIF with CBP/p300 and therefore, HIF’s transactivation activity 
is reduced (22). Interestingly, HIF induces the expression of two 
of its negative regulators, PHD2 and PHD3, in order to ensure its 
own rapid degradation upon reoxygenation (19, 23). However, in 
conditions of chronic hypoxia, once the transcriptional adaptive 
program has been triggered, HIF-α levels drop again to avoid 
sustained HIF signaling and assure cell survival (24).
In the context of the canonical HIF signaling pathway, so 
far there are relatively few DUBs reported in the literature, and 
reports are mostly focused on the impact on HIF-1α (Figure 1 
upper part). USP20 (also called pVHL interacting DUB2, VDU2) 
was the first DUB to be described to reverse pVHL-mediated 
HIF-1α ubiquitination (25). In turn, USP20 is a pVHL target (26). 
MCPIP1 also deubiquitinates HIF-1α to promote angiogenesis 
(27). In the context of ciliogenesis, USP8 has been found to bind 
to HIF-1α’s PAS domain and to partially protect HIF-1α from 
degradation (28). More recently, UCHL1 has been shown to be a 
positive regulator of HIF-1α protein stability acting on HIF-1α’s 
ODDD (29).
THe nOn-CAnOniCAL HiF SiGnALinG
Not surprisingly because of HIF’s crucial role in cell fate, many 
more proteins have been described to be involved in the control 
of its stability (Figure 1 lower part). The heat-shock protein 90 
(HSP90) that interacts with the PAS domain of HIF-α regulates 
its degradation in an O2/PHD/pVHL-independent manner (30). 
HSP90 competes with RACK1 for binding to HIF-α and prevents 
the recruitment of the elongin C/B Ub E3 ligase complex (31). 
A similar mechanism has been proposed for HIF-α activation 
by ErbB4 (32). As for other HSP90 client proteins, Cullin5 also 
regulates HIF-α degradation independently of elongin C/B func-
tion (33). The tumor suppressors p53, TAp73, and pTEN promote 
the Ub-mediated degradation of HIF-1α via recruitment of the 
Ub E3 ligase Mdm2 (34–36). Furthermore, Fbw7 ubiquitinates 
and induces HIF-1α degradation following phosphorylation by 
GSK3β (37, 38). Interestingly, this degradation can be antago-
nized by the Ub-specific protease (USP28) (38). Until now, this 
is the only non-canonical Ub E3 ligase–DUB pair identified for 
proteasomal degradation of HIF-α. HAF, the hypoxia-associated 
factor, seems to play a dual role in the control of HIF-α stabil-
ity and/or activity. While HAF acts as an Ub E3 ligase targeting 
HIF-1α for degradation independently of oxygen availability, 
hypoxia-induced SUMOylated HAF promotes HIF-2α transacti-
vation without affecting its stability (39, 40). Furthermore, RNF4 
controls the levels of SUMOylated HIF-2α (41). USP19 seems to 
be required for the hypoxic accumulation of HIF-1α, though the 
effect is not dependent on its deubiquitinase activity (42). USP19 
is further substrate of Siah-1 and Siah-2 Ub E3 ligases, which also 
control the stability of PHD1, PHD3, and FIH (43–45). Thus, 
further studies are necessary to clarify the direct impact of USP19 
in HIF-1α ubiquitination.
FiGURe 1 | involvement of ubiquitinating and deubiquitinating enzymes in the regulation of HiF-α. Destabilizing and stabilizing E3 ligases targeting HIF-α 
are pictured in red and green, respectively and DUBs are depicted in blue. E3 ligases that have been described to target HIF-α for proteasomal degradation are 
marked with a *; † refers to lysosomal HIF-α degradation.
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The chaperone-dependent Ub ligase CHIP targets HIF-1α but 
not HIF-2α for degradation either by the proteasome or by the 
autophagic machinery, the second big protein degradation and 
recycling pathway that has been implicated in the elimination of 
ubiquitinated HIF-α (46–49). In this regard, Cezanne (OTUD7B), 
a deubiquitinase targeting K11 Ub chains (50), has been reported 
to protect HIF-1α from lysosomal degradation. While this pro-
cess is independent of HIF-1α prolyl hydroxylation, it depends on 
the presence of pVHL (51).
Calpain and the activation of the forkhead transcription factor 
FOXO4 destabilize HIF-α, although the underlying molecular 
mechanisms are unknown (52, 53). Further studies are also 
needed to characterize the role of Parkin in the regulation of 
HIF-α, based on its identification within the Parkin-dependent 
ubiquitinome by a proteomic approach (54). In contrast with 
all the previous reports, it is worth mentioning the role played 
by the Ub E3 ligase TRAF6. TRAF6 increases HIF-1α but not 
HIF-2α polyK-63 ubiquitination and protects the protein from 
proteasomal degradation (55).
In addition to HIF-α stability, mRNA expression and activity 
of the transcriptional complex fine-tune HIF regulation. In this 
regard, USP52 is required for the protection of HIF-1α (but not 
HIF-2α) mRNA from premature degradation and therefore, 
allows the normal hypoxic induction of HIF-1α (56). The case of 
USP52 is somewhat special as this protein, although structurally 
related to the family of USPs, lacks the catalytic cysteine (57). 
Besides protecting HIF-1α protein from its degradation, Cezanne’s 
catalytical activity is also required for maintaining basal levels of 
the E2F1 transcription factor. Moniz et al. demonstrated that E2F1 
controls the expression of HIF-2α mRNA and therefore, established 
an indirect role of the DUB Cezanne in HIF-2α expression (58).
Finally, a number of DUBs have been shown to regulate 
transcription factors and signaling pathways that cross talk with 
HIFs, likely contributing to the complexity and specificity of the 
cellular hypoxic response, even though they go beyond the scope 
of this review (59–61).
ReGULATiOn OF DUBs BY HYPOXiA
As for other enzymes, there are several possible layers of regula-
tion of DUB activity. Next to the transcriptional regulation, the 
stability and translation of the mRNA can be regulated by 
mRNA-processing enzymes. The turnover and therefore, the 
availability of the mature protein can be set by a variety of PTMs. 
PTMs can also interfere with the binding of the DUBs to their 
target proteins or other interactors, as well as modulate revers-
ibly and irreversibly the (auto) catalytical activity of the DUB. 
Hypoxia, being an extreme cellular stress condition, should be 
able to regulate deubiquitinating activity on all the possible dif-
ferent layers in order to adapt DUB functions to the cell’s needs. 
However, the literature about the regulation of specific DUBs 
by hypoxia (1% O2, if not specified differently) is still scarce and 
March 2016 | Volume 6 | Article 534
Schober and Berra DUBs in Tumor HIF Signaling
Frontiers in Oncology | www.frontiersin.org
almost exclusively restricted to transcriptional regulation. For 
instance, the expression of USP13 is reduced upon treatment with 
as little as 6 h of 2% O2 in melanoma cell lines (59). The reduc-
tion of the mRNA also translates to the protein level and causes 
the loss of Siah-2 stabilization. Similarly, in colon cancer cells 
hypoxia reduces USP46 mRNA and protein levels and, therefore, 
diminishes USP46’s stabilizing effect on the tumor suppressors 
PHLPP1 and PHLPP2, conferring to the colon cancer cells an 
increased paclitaxel resistance (62, 63). Guo et al. provide more 
detailed information about the hypoxia-mediated transcriptional 
regulation of the UCH CYLD. They suggest that the decrease of 
CYLD mRNA and protein seen in glioblastoma cells is due to the 
hypoxia-induced increase of the transcriptional repressors Snail 
and Hes1 (64). In contrast, hypoxia has been shown to increase 
Cezanne via p38 MAPK (65).
An et al. claimed that CYLD is targeted for proteasomal deg-
radation after interaction with the HPV E6 protein in hypoxia 
(66). This is to date the only report of a posttranslational regula-
tion of DUB activity by hypoxia. However, Lee et  al. present 
evidence that the activity of many, if not most, DUBs depends 
on the redox state of the cell. They show that the catalytically 
active cysteine residue can be oxidized, for instance, by intra-
cellular hydrogen peroxide, leading to the abolishment of the 
deubiquitinating activity. The inactivating oxidation can be 
reversed in the presence of reducing agents, such as DTT, or 
prevented by antioxidants (67). As hypoxia and mitochondrial 
ROS production are intrinsically linked it might not be too 
far-fetched to propose that hypoxia directly modulates DUB 
activity via ROS.
DYSReGULATiOn OF HYPOXiA-ReLATeD 
DUBs in CAnCeR
Given the importance of Ub-mediated changes in protein func-
tion and homeostasis, it is not by chance that the entire process 
is highly regulated. Disruption of the ubiquitination cycle by 
mutations or altered expression of specific components within 
the cascade has been associated with several disorders. In par-
ticular, more than 30 DUBs have been associated with cancer 
directly or indirectly. Both, the loss of a specific DUB activity or 
its hyperactivity are non-desired events if the targets are tumor 
suppressors or oncogenes, respectively. Recurrent mutations of 
DUBs are rare in cancer with only few exceptions. Gene fusions 
with RUNX are reported for USP42 and USP16 in hematologic 
diseases, such as chronic myelomonocytic leukemia and acute 
myeloid leukemia. However, dysregulated mRNA levels of DUBs 
are implicated in many malignancies. Here, we will focus only on 
a few examples of hypoxia-related DUBs, for a more extensive 
overview please refer to the very comprehensive review by 
D’Arcy et al. (68).
Germline mutations of the tumor-suppressor gene CYLD are 
prevalent in familial cylindromatosis, a genetic condition that 
leads to predisposition for developing multiple skin tumors (69, 
70). In addition, CYLD deubiquitinating activity has been seen 
to be abolished in different cancers on the protein level by inac-
tivating phosphorylations or destabilizing polyubiquitination 
(71). More recently, it has been reported that USP8 is frequently 
mutated in adenomas causing Cushing’s disease (72).
USP28 is a DUB whose overexpression has been reported 
in breast and colon cancer and glioblastoma (73, 74). A recent 
publication has proposed USP28 to be a potential predictive 
marker in bladder cancer, as they found correlation of USP28 
with tumor histological grade, clinical stage, recurrence, and 
survival (75). Similar to USP28, UCHL1 has also been proposed 
to be a useful biomarker, being overexpressed in gastric cancer 
(76) and in myeloma (77), and epigenetically down-regulated in 
colorectal cancer (78). As mentioned above, downregulation of 
USP46 may serve as a biomarker of resistance to chemotherapy 
in colon cancer (63). Finally, despite being inconsistent to its 
role in the regulation of HIF-1α and HIF-2α, decreased Cezanne 
expression is associated with the progression and poor prognosis 
in hepatocellular carcinoma (79).
DUBs AS DRUGGABLe TARGeTS FOR 
THeRAPY
Modulators of individual UPS components are emerging as a 
novel class of anticancer drugs. The initial research focus had 
been directed toward targeting the proteasome, with activity 
described for many compounds with proteasome inhibitory 
activity, including bortezomib. Because Ub E3 ligases provide 
substrate specificity, their direct targeting may avoid the del-
eterious side effects associated with the global inhibition of the 
proteasome, making them interesting candidates as drug targets. 
Nutlin-3 and JNJ-26854165 are classic examples directed against 
the Ub E3 ligase MDM2 and are currently undergoing clinical 
evaluation as anticancer therapy.
Newly arising, DUBs may serve as equally or more useful 
targets. Indeed, DUBs are highly specialized and evolutionary 
linked to proteases, a typified pharmaceutical target class for drug 
discovery, thanks to their well-characterized catalytical domain. 
Several partial and specific inhibitors against a small number of 
DUBs have been developed, have proved active in preclinical 
studies as reviewed recently by D’Arcy and Linder (80), and have 
provided feasibility for targeting these enzymes for anticancer 
purposes. Among them, HBX 41,108 is a partially selective USP 
inhibitor because it inhibits USP5, USP7, USP8, and UCHL3 in 
addition to caspase 3 (81). This is to our knowledge the only DUB 
inhibitor so far described as targeting one of the DUBs linked to 
the HIF signaling pathway. Interestingly, the inhibition of USP8 
suppresses growth of gefitinib-resistant non-small cell lung 
cancer cells, though no link to the potential impact on HIF-1α is 
reported (82). It is tempting to speculate about new drugs directed 
against hypoxia-related DUBs that succeed to fight intratumoral 
hypoxia-signaling in the coming years.
COnCLUSiOn
HIF-α protein homeostasis is tightly controlled in healthy cells in 
order to avoid inappropriate activation of HIF signaling. A variety 
of E3 ligases and DUBs are involved in this task by triggering and 
protecting HIF-α from its degradation, respectively. Permanent 
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activation of the HIF signaling pathway has been found in many 
tumors and seems to be beneficial for tumor growth and cancer 
progression. In most cases, the reason for sustained HIF-α pro-
tein levels in the tumor cells are still not revealed, but a possible 
mechanism is the pathological increase of HIF-α specific DUB 
activity. In recent years, the dysregulation of deubiquinating 
enzymes in cancer (and other diseases) has become of increasing 
interest, and alterations of their expression and activities have 
been shown to have diagnostic value. Whether cancer-related 
events that lead to the upregulation of DUB activity are the 
primary cause of uncontrolled HIF signaling, or whether initial 
hypoxia upregulates DUB expression as a positive feed-back-loop 
is not determined. But in the light of DUBs being druggable 
enzymes, it is important to understand their implications in HIF 
and tumor hypoxia-signaling.
AUTHOR COnTRiBUTiOnS
ASS and EB contributed with review writing, editing, and final 
approval of the manuscript.
ACKnOwLeDGMenTS
The authors would like to thank all the laboratory members for 
discussions and comments. We apologize to the many research 
groups whose work was not cited due to space constraints.
FUnDinG
Our research is supported by the Plan Nacional of I+D BFU-
2013-46647. ASS is a Liverpool-bioGUNE partnership fellow.
ReFeRenCeS
1. Clague MJ, Heride C, Urbe S. The demographics of the ubiquitin system. 
Trends Cell Biol (2015) 25:417–26. doi:10.1016/j.tcb.2015.03.002 
2. Fraile JM, Quesada V, Rodriguez D, Freije JM, Lopez-Otin C. Deubiquitinases 
in cancer: new functions and therapeutic options. Oncogene (2012) 31:2373–
88. doi:10.1038/onc.2011.443 
3. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem (2012) 
81:203–29. doi:10.1146/annurev-biochem-060310-170328 
4. Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. 
Biochem J (2015) 467:191. doi:10.1042/bj4670191 
5. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression 
and targets for cancer therapy. Trends Pharmacol Sci (2012) 33:207–14. 
doi:10.1016/j.tips.2012.01.005 
6. Wang GL, Semenza GL. Purification and characterization of hypoxia- 
inducible factor 1. J Biol Chem (1995) 270:1230–7. doi:10.1074/jbc.270.3.1230 
7. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein 
is rapidly degraded by the ubiquitin-proteasome system under normoxic 
conditions. Its stabilization by hypoxia depends on redox-induced changes. 
J Biol Chem (1997) 272:22642–7. doi:10.1074/jbc.272.36.22642 
8. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible 
factor 1alpha is mediated by an O2-dependent degradation domain via the 
ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1998) 95:7987–92. 
doi:10.1073/pnas.95.14.7987 
9. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, 
et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for 
oxygen-dependent proteolysis. Nature (1999) 399:271–5. doi:10.1038/20459 
10. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. 
Overexpression of hypoxia-inducible factor 1alpha in common human can-
cers and their metastases. Cancer Res (1999) 59:5830–5. 
11. Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, et al. 
HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and 
treatment outcome. Int J Cancer (2007) 120:1451–8. doi:10.1002/ijc.22436 
12. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry 
in hypoxic tumour growth and progression. Nat Rev Cancer (2012) 12:9–22. 
doi:10.1038/nrc3183
13. Berra E, Roux D, Richard DE, Pouyssegur J. Hypoxia-inducible factor-1 alpha 
(HIF-1 alpha) escapes O(2)-driven proteasomal degradation irrespective of its 
subcellular localization: nucleus or cytoplasm. EMBO Rep (2001) 2:615–20. 
doi:10.1093/embo-reports/kve130 
14. Baek JH, Liu YV, McDonald KR, Wesley JB, Hubbi ME, Byun H, et  al. 
Spermidine/spermine-N1-acetyltransferase 2 is an essential component of the 
ubiquitin ligase complex that regulates hypoxia-inducible factor 1alpha. J Biol 
Chem (2007) 282:23572–80. doi:10.1074/jbc.M703504200 
15. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that 
modify HIF. Science (2001) 294:1337–40. doi:10.1126/science.1066373 
16. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR, et al. 
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases 
that regulate HIF by prolyl hydroxylation. Cell (2001) 107:43–54. doi:10.1016/
S0092-8674(01)00507-4 
17. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha tar-
geted for VHL-mediated destruction by proline hydroxylation: implications 
for O2 sensing. Science (2001) 292:464–8. doi:10.1126/science.1059817 
18. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et  al. 
Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by 
O2-regulated prolyl hydroxylation. Science (2001) 292:468–72. doi:10.1126/
science.1059796 
19. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF pro-
lyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of 
HIF-1alpha in normoxia. EMBO J (2003) 22:4082–90. doi:10.1093/emboj/
cdg392 
20. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 
1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A (1993) 
90:4304–8. doi:10.1073/pnas.90.9.4304 
21. Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA, et al. An 
essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad 
Sci U S A (1996) 93:12969–73. doi:10.1073/pnas.93.23.12969 
22. Lando D, Peet DJ, Whelan DA, Gorman JJ, Whitelaw ML. Asparagine hydrox-
ylation of the HIF transactivation domain a hypoxic switch. Science (2002) 
295:858–61. doi:10.1126/science.1068592 
23. Pescador N, Cuevas Y, Naranjo S, Alcaide M, Villar D, Landázuri MO, et al. 
Identification of a functional hypoxia-responsive element that regulates the 
expression of the egl nine homologue 3 (egln3/phd3) gene. Biochem J (2005) 
390:189–97. doi:10.1042/bj20042121 
24. Ginouves A, Ilc K, Macias N, Pouyssegur J, Berra E. PHDs overactivation during 
chronic hypoxia “desensitizes” HIFalpha and protects cells from necrosis. Proc 
Natl Acad Sci U S A (2008) 105:4745–50. doi:10.1073/pnas.0705680105 
25. Li Z, Wang D, Messing EM, Wu G. VHL protein-interacting deubiquitinating 
enzyme 2 deubiquitinates and stabilizes HIF-1alpha. EMBO Rep (2005) 
6:373–8. doi:10.1038/sj.embor.7400377 
26. Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G. Identification of a deu-
biquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor 
suppressor. Biochem Biophys Res Commun (2002) 294:700–9. doi:10.1016/
S0006-291X(02)00534-X 
27. Roy A, Zhang M, Saad Y, Kolattukudy PE. Antidicer RNAse activity of 
monocyte chemotactic protein-induced protein-1 is critical for inducing 
angiogenesis. Am J Physiol Cell Physiol (2013) 305:C1021–32. doi:10.1152/
ajpcell.00203.2013 
28. Troilo A, Alexander I, Muehl S, Jaramillo D, Knobeloch K-P, Krek W. HIF1α 
deubiquitination by USP8 is essential for ciliogenesis in normoxia. EMBO Rep 
(2014) 15:77–85. doi:10.1002/embr.201337688 
29. Goto Y, Zeng L, Yeom CJ, Zhu Y, Morinibu A, Shinomiya K, et al. UCHL1 
provides diagnostic and antimetastatic strategies due to its deubiquitinating 
effect on HIF-1alpha. Nat Commun (2015) 6:6153. doi:10.1038/ncomms7153 
30. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, Neckers LM. Hsp90 
regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 
March 2016 | Volume 6 | Article 536
Schober and Berra DUBs in Tumor HIF Signaling
Frontiers in Oncology | www.frontiersin.org
alpha-degradative pathway. J Biol Chem (2002) 277:29936–44. doi:10.1074/
jbc.M204733200 
31. Liu YV, Baek JH, Zhang H, Diez R, Cole RN, Semenza GL. RACK1 competes 
with HSP90 for binding to HIF-1alpha and is required for O(2)-independent 
and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell (2007) 
25:207–17. doi:10.1016/j.molcel.2007.01.001 
32. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE, et al. 
Interaction with ErbB4 promotes hypoxia-inducible factor-1alpha signaling. 
J Biol Chem (2012) 287:9659–71. doi:10.1074/jbc.M111.299537 
33. Ehrlich ES, Wang T, Luo K, Xiao Z, Niewiadomska AM, Martinez T, et  al. 
Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. 
Proc Natl Acad Sci U S A (2009) 106:20330–5. doi:10.1073/pnas.0810571106 
34. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. 
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-in-
ducible factor 1alpha. Genes Dev (2000) 14:34–44. doi:10.1101/gad.14.1.34
35. Joshi S, Singh AR, Durden DL. MDM2 regulates hypoxic hypoxia- 
inducible factor 1alpha stability in an E3 ligase, proteasome, and PTEN-
phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem (2014) 
289:22785–97. doi:10.1074/jbc.M114.587493 
36. Amelio I, Inoue S, Markert EK, Levine AJ, Knight RA, Mak TW, et al. TAp73 
opposes tumor angiogenesis by promoting hypoxia-inducible factor 1alpha 
degradation. Proc Natl Acad Sci U S A (2015) 112:226–31. doi:10.1073/
pnas.1410609111 
37. Cassavaugh JM, Hale SA, Wellman TL, Howe AK, Wong C, Lounsbury KM. 
Negative regulation of HIF-1alpha by an FBW7-mediated degradation pathway 
during hypoxia. J Cell Biochem (2011) 112:3882–90. doi:10.1002/jcb.23321 
38. Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth, migration, 
and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. 
Blood (2012) 119:1292–301. doi:10.1182/blood-2011-08-375014 
39. Koh MY, Darnay BG, Powis G. Hypoxia-associated factor, a novel E3-ubiquitin 
ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading 
to its oxygen-independent degradation. Mol Cell Biol (2008) 28:7081–95. 
doi:10.1128/MCB.00773-08 
40. Koh MY, Nguyen V, Lemos R Jr, Darnay BG, Kiriakova G, Abdelmelek M, et al. 
Hypoxia-induced SUMOylation of E3 ligase HAF determines specific activa-
tion of HIF2 in clear-cell renal cell carcinoma. Cancer Res (2015) 75:316–29. 
doi:10.1158/0008-5472.CAN-13-2190 
41. van Hagen M, Overmeer RM, Abolvardi SS, Vertegaal AC. RNF4 and VHL 
regulate the proteasomal degradation of SUMO-conjugated hypoxia-inducible 
factor-2alpha. Nucleic Acids Res (2010) 38:1922–31. doi:10.1093/nar/gkp1157 
42. Altun M, Zhao B, Velasco K, Liu H, Hassink G, Paschke J, et al. Ubiquitin-
specific protease 19 (USP19) regulates hypoxia-inducible factor 1α (HIF-1α) 
during hypoxia. J Biol Chem (2012) 287:1962–9. doi:10.1074/jbc.M111.305615 
43. Nakayama K, Frew IJ, Hagensen M, Skals M, Habelhah H, Bhoumik A, 
et  al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha 
abundance, and modulates physiological responses to hypoxia. Cell (2004) 
117:941–52. doi:10.1016/j.cell.2004.06.001 
44. Fukuba H, Yamashita H, Nagano Y, Jin HG, Hiji M, Ohtsuki T, et al. Siah-1 
facilitates ubiquitination and degradation of factor inhibiting HIF-1alpha 
(FIH). Biochem Biophys Res Commun (2007) 353:324–9. doi:10.1016/j.
bbrc.2006.12.051 
45. Velasco K, Zhao B, Callegari S, Altun M, Liu H, Hassink G, et al. An N-terminal 
SIAH-interacting motif regulates the stability of the ubiquitin specific protease 
(USP)-19. Biochem Biophys Res Commun (2013) 433:390–5. doi:10.1016/j.
bbrc.2013.02.094 
46. Bento CF, Fernandes R, Ramalho J, Marques C, Shang F, Taylor A, et al. The 
chaperone-dependent ubiquitin ligase CHIP targets HIF-1α for degradation 
in the presence of methylglyoxal. PLoS One (2010) 5:e15062. doi:10.1371/
journal.pone.0015062 
47. Luo W, Zhong J, Chang R, Hu H, Pandey A, Semenza GL. Hsp70 and CHIP 
selectively mediate ubiquitination and degradation of hypoxia-inducible 
factor (HIF)-1alpha but not HIF-2alpha. J Biol Chem (2010) 285:3651–63. 
doi:10.1074/jbc.M109.068577 
48. Ferreira JV, Fofo H, Bejarano E, Bento CF, Ramalho JS, Girao H, et al. STUB1/
CHIP is required for HIF1A degradation by chaperone-mediated autophagy. 
Autophagy (2013) 9:1349–66. doi:10.4161/auto.25190 
49. Hubbi ME, Hu H, Kshitiz, Ahmed I, Levchenko A, Semenza GL. Chaperone-
mediated autophagy targets hypoxia-inducible factor-1alpha (HIF-1alpha) 
for lysosomal degradation. J Biol Chem (2013) 288:10703–14. doi:10.1074/
jbc.M112.414771 
50. Bremm A, Freund SM, Komander D. Lys11-linked ubiquitin chains adopt 
compact conformations and are preferentially hydrolyzed by the deu-
biquitinase Cezanne. Nat Struct Mol Biol (2010) 17:939–47. doi:10.1038/
nsmb.1873 
51. Bremm A, Moniz S, Mader J, Rocha S, Komander D. Cezanne (OTUD7B) 
regulates HIF-1alpha homeostasis in a proteasome-independent manner. 
EMBO Rep (2014) 15:1268–77. doi:10.15252/embr.201438850 
52. Tang TT-L, Lasky LA. The forkhead transcription factor FOXO4 induces 
the down-regulation of hypoxia-inducible factor 1 alpha by a von Hippel-
Lindau protein-independent mechanism. J Biol Chem (2003) 278:30125–35. 
doi:10.1074/jbc.M302042200 
53. Zhou J, Kohl R, Herr B, Frank R, Brune B. Calpain mediates a von Hippel-
Lindau protein-independent destruction of hypoxia-inducible factor-1alpha. 
Mol Biol Cell (2006) 17:1549–58. doi:10.1091/mbc.E05-08-0770 
54. Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi SP, et al. 
Landscape of the PARKIN-dependent ubiquitylome in response to mitochon-
drial depolarization. Nature (2013) 496:372–6. doi:10.1038/nature12043 
55. Sun H, Li XB, Meng Y, Fan L, Li M, Fang J. TRAF6 upregulates expression of 
HIF-1alpha and promotes tumor angiogenesis. Cancer Res (2013) 73:4950–9. 
doi:10.1158/0008-5472.CAN-13-0370 
56. Bett JS, Ibrahim AF, Garg AK, Kelly V, Pedrioli P, Rocha S, et al. The P-body 
component USP52/PAN2 is a novel regulator of HIF1A mRNA stability. 
Biochem J (2013) 451:185–94. doi:10.1042/BJ20130026 
57. Quesada V, Diaz-Perales A, Gutierrez-Fernandez A, Garabaya C, Cal S, Lopez-
Otin C. Cloning and enzymatic analysis of 22 novel human ubiquitin-specific 
proteases. Biochem Biophys Res Commun (2004) 314:54–62. doi:10.1016/j.
bbrc.2003.12.050 
58. Moniz S, Bandarra D, Biddlestone J, Campbell KJ, Komander D, Bremm A, 
et  al. Cezanne regulates E2F1-dependent HIF2alpha expression. J Cell Sci 
(2015) 128:3082–93. doi:10.1242/jcs.168864 
59. Scortegagna M, Subtil T, Qi J, Kim H, Zhao W, Gu W, et al. USP13 enzyme 
regulates Siah2 ligase stability and activity via noncatalytic ubiquitin-binding 
domains. J Biol Chem (2011) 286:27333–41. doi:10.1074/jbc.M111.218214 
60. Zheng X, Zhai B, Koivunen P, Shin SJ, Lu G, Liu J, et al. Prolyl hydroxylation 
by EglN2 destabilizes FOXO3a by blocking its interaction with the USP9x 
deubiquitinase. Genes Dev (2014) 28:1429–44. doi:10.1101/gad.242131.114 
61. Kim JO, Kim SR, Lim KH, Kim JH, Ajjappala B, Lee HJ, et al. Deubiquitinating 
enzyme USP37 regulating oncogenic function of 14-3-3gamma. Oncotarget 
(2015) 6:36551–76. doi:10.18632/oncotarget.5336 
62. Li X, Stevens PD, Yang H, Gulhati P, Wang W, Evers BM, et al. The deubiq-
uitination enzyme USP46 functions as a tumor suppressor by controlling 
PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene 
(2013) 32:471–8. doi:10.1038/onc.2012.66 
63. Wen YA, Stevens PD, Gasser ML, Andrei R, Gao T. Downregulation of PHLPP 
expression contributes to hypoxia-induced resistance to chemotherapy in colon 
cancer cells. Mol Cell Biol (2013) 33:4594–605. doi:10.1128/MCB.00695-13 
64. Guo J, Shinriki S, Su Y, Nakamura T, Hayashi M, Tsuda Y, et  al. Hypoxia 
suppresses cylindromatosis (CYLD) expression to promote inflammation 
in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. 
Oncotarget (2014) 5:6353–64. doi:10.18632/oncotarget.2216 
65. Luong le A, Fragiadaki M, Smith J, Boyle J, Lutz J, Dean JL, et al. Cezanne 
regulates inflammatory responses to hypoxia in endothelial cells by targeting 
TRAF6 for deubiquitination. Circ Res (2013) 112:1583–91. doi:10.1161/
CIRCRESAHA.111.300119 
66. An J, Mo D, Liu H, Veena MS, Srivatsan ES, Massoumi R, et al. Inactivation of 
the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB 
activation. Cancer Cell (2008) 14:394–407. doi:10.1016/j.ccr.2008.10.007 
67. Lee JG, Baek K, Soetandyo N, Ye Y. Reversible inactivation of deubiquitinases 
by reactive oxygen species in vitro and in cells. Nat Commun (2013) 4:1568. 
doi:10.1038/ncomms2532 
68. D’Arcy P, Wang X, Linder S. Deubiquitinase inhibition as a cancer 
therapeutic strategy. Pharmacol Ther (2015) 147:32–54. doi:10.1016/j.
pharmthera.2014.11.002 
69. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, et  al. 
Identification of the familial cylindromatosis tumour-suppressor gene. Nat 
Genet (2000) 25:160–5. doi:10.1038/76006 
March 2016 | Volume 6 | Article 537
Schober and Berra DUBs in Tumor HIF Signaling
Frontiers in Oncology | www.frontiersin.org
70. Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen J, et  al. 
Linkage and LOH studies in 19 cylindromatosis families show no evidence of 
genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13. 
Hum Genet (2000) 106:58–65. doi:10.1007/s004399900227 
71. Massoumi R. CYLD: a deubiquitination enzyme with multiple roles in cancer. 
Future Oncol (2011) 7:285–97. doi:10.2217/fon.10.187 
72. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein 
F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. 
Nat Genet (2015) 47:31–8. doi:10.1038/ng.3166 
73. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, 
et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat 
Cell Biol (2007) 9:765–74. doi:10.1038/ncb1601 
74. Wang Z, Song Q, Xue J, Zhao Y, Qin S. Ubiquitin-specific protease 28 is overex-
pressed in human glioblastomas and contributes to glioma tumorigenicity by 
regulating MYC expression. Exp Biol Med (Maywood) (2015) 241(3):255–64. 
doi:10.1177/1535370215595468 
75. Guo G, Xu Y, Gong M, Cao Y, An R. USP28 is a potential prognostic 
marker for bladder cancer. Tumour Biol (2014) 35:4017–22. doi:10.1007/
s13277-013-1525-1 
76. Gu YY, Yang M, Zhao M, Luo Q, Yang L, Peng H, et al. The de-ubiquitinase 
UCHL1 promotes gastric cancer metastasis via the Akt and Erk1/2 pathways. 
Tumour Biol (2015) 36(11):8379–87. doi:10.1007/s13277-015-3566-0 
77. Hussain S, Bedekovics T, Chesi M, Bergsagel PL, Galardy PJ. UCHL1 is a 
biomarker of aggressive multiple myeloma required for disease progression. 
Oncotarget (2015) 6(38):40704–18. doi:10.18632/oncotarget.5727 
78. Abdelmaksoud-Dammak R, Saadallah-Kallel A, Miladi-Abdennadher 
I, Ayedi L, Khabir A, Sallemi-Boudawara T, et  al. CpG methylation of 
ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) and P53 mutation 
pattern in sporadic colorectal cancer. Tumour Biol (2015) 1–8. doi:10.1007/
s13277-015-3902-4 
79. Wang JH, Wei W, Guo ZX, Shi M, Guo RP. Decreased Cezanne expression is 
associated with the progression and poor prognosis in hepatocellular carci-
noma. J Transl Med (2015) 13:41. doi:10.1186/s12967-015-0396-1 
80. D’Arcy P, Linder S. Molecular pathways: translational potential of deubiquiti-
nases as drug targets. Clin Cancer Res (2014) 20:3908–14. doi:10.1158/1078-
0432.CCR-14-0568 
81. Colombo M, Vallese S, Peretto I, Jacq X, Rain JC, Colland F, et al. Synthesis 
and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicar-
bonitrile analogues as potential inhibitors of deubiquitinating enzymes. 
ChemMedChem (2010) 5:552–8. doi:10.1002/cmdc.200900409 
82. Jeong CH. Inhibition of ubiquitin-specific peptidase 8 suppresses growth 
of gefitinib-resistant non-small cell lung cancer cells by inducing apoptosis. 
J Cancer Prev (2015) 20:57–63. doi:10.15430/JCP.2015.20.1.57 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Schober and Berra. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License (CC BY). The use, distribu-
tion or reproduction in other forums is permitted, provided the original author(s) 
or licensor are credited and that the original publication in this journal is cited, in 
accordance with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
